Rizatriptan Benzoate

×

Overview

What is Rizatriptan Benzoate?

Rizatriptan benzoate tablets, USP contain rizatriptan benzoate, a selective 5-hydroxytryptamine (5-HT) receptor agonist.

Rizatriptan benzoate, USP is described chemically as: -dimethyl-5-(1-1,2,4-triazol-1-ylmethyl)-1-indole-3-ethanamine monobenzoate and its structural formula is:

Its molecular formula is CHN•CHO, representing a molecular weight of the free base of 269.4. Rizatriptan benzoate, USP is a white to off-white, crystalline solid that is soluble in water at about 42 mg per mL (expressed as free base) at 25°C.

Rizatriptan benzoate tablets are available for oral administration in strengths of 5 mg and 10 mg (corresponding to 7.265 mg or 14.53 mg of the benzoate salt, respectively). Each compressed tablet contains the following inactive ingredients: lactose monohydrate, microcrystalline cellulose, starch (corn starch), pregelatinized starch ( maize), colloidal silicon dioxide, ferric oxide (red), and magnesium stearate.

What does Rizatriptan Benzoate look like?

What are the available doses of Rizatriptan Benzoate?

Rizatriptan benzoate tablets, USP:

What should I talk to my health care provider before I take Rizatriptan Benzoate?

How should I use Rizatriptan Benzoate?

Rizatriptan benzoate is a serotonin (5-HT) receptor agonist (triptan) indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years of age ()

Limitations of Use

The recommended starting dose of rizatriptan benzoate tablets is either 5 mg or 10 mg for the acute treatment of migraines in adults. The 10 mg dose may provide a greater effect than the 5 mg dose, but may have a greater risk of adverse reactions

Redosing in Adults

Although the effectiveness of a second dose or subsequent doses has not been established in placebo-controlled trials, if the migraine headache returns, a second dose may be administered 2 hours after the first dose. The maximum daily dose should not exceed 30 mg in any 24-hour period. The safety of treating, on average, more than four headaches in a 30-day period has not been established.

What interacts with Rizatriptan Benzoate?

Sorry No Records found

What are the warnings of Rizatriptan Benzoate?

Sorry No Records found

What are the precautions of Rizatriptan Benzoate?

Sorry No Records found

What are the side effects of Rizatriptan Benzoate?

Sorry No records found

What should I look out for while using Rizatriptan Benzoate?

History of ischemic heart disease or coronary artery vasospasm ()

History of stroke or transient ischemic attack ()

Peripheral vascular disease ()

Ischemic bowel disease ()

Uncontrolled hypertension ()

Recent (within 24 hours) use of another 5-HTagonist (e.g., another triptan), or of an ergotamine-containing medication ()

Hemiplegic or basilar migraine ()

MAO-A inhibitor used in the past 2 weeks ()

Hypersensitivity to rizatriptan benzoate ()

What might happen if I take too much Rizatriptan Benzoate?

No overdoses of rizatriptan benzoate were reported during clinical trials in adults.

Some adult patients who received 40 mg of rizatriptan benzoate either a single dose or as two doses with a 2-hour interdose interval had dizziness and somnolence.

In a clinical pharmacology study in which 12 adult subjects received rizatriptan benzoate, at total cumulative doses of 80 mg (given within four hours), two of the subjects experienced syncope, dizziness, bradycardia including third degree AV block, vomiting, and/or incontinence.

In the long-term, open label study, involving 606 treated pediatric migraineurs 12 to 17 years of age (of which 432 were treated for at least 12 months), 151 patients (25%) took two 10 mg doses of rizatriptan benzoate orally disintegrating tablets within a 24 hour period. Adverse reactions for 3 of these patients included abdominal discomfort, fatigue, and dyspnea.

In addition, based on the pharmacology of rizatriptan benzoate, hypertension or myocardial ischemia could occur after overdosage. Gastrointestinal decontamination, (i.e., gastric lavage followed by activated charcoal) should be considered in patients suspected of an overdose with rizatriptan benzoate. Clinical and electrocardiographic monitoring should be continued for at least 12 hours, even if clinical symptoms are not observed.

The effects of hemo- or peritoneal dialysis on serum concentrations of rizatriptan are unknown.

How should I store and handle Rizatriptan Benzoate?

Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.] Protect from freezing.Product: 63629-7433NDC: 63629-7433-1 10 TABLET in a BOTTLENDC: 63629-7433-2 6 TABLET in a BOTTLENDC: 63629-7433-3 90 TABLET in a BOTTLENDC: 63629-7433-4 9 TABLET in a BOTTLEProduct: 63629-7433NDC: 63629-7433-1 10 TABLET in a BOTTLENDC: 63629-7433-2 6 TABLET in a BOTTLENDC: 63629-7433-3 90 TABLET in a BOTTLENDC: 63629-7433-4 9 TABLET in a BOTTLEProduct: 63629-7433NDC: 63629-7433-1 10 TABLET in a BOTTLENDC: 63629-7433-2 6 TABLET in a BOTTLENDC: 63629-7433-3 90 TABLET in a BOTTLENDC: 63629-7433-4 9 TABLET in a BOTTLEProduct: 63629-7433NDC: 63629-7433-1 10 TABLET in a BOTTLENDC: 63629-7433-2 6 TABLET in a BOTTLENDC: 63629-7433-3 90 TABLET in a BOTTLENDC: 63629-7433-4 9 TABLET in a BOTTLEProduct: 63629-7433NDC: 63629-7433-1 10 TABLET in a BOTTLENDC: 63629-7433-2 6 TABLET in a BOTTLENDC: 63629-7433-3 90 TABLET in a BOTTLENDC: 63629-7433-4 9 TABLET in a BOTTLE

×

Clinical Information

Chemical Structure

No Image found

Clinical Pharmacology

Rizatriptan binds with high affinity to human cloned 5-HT receptors. Rizatriptan presumably exerts its therapeutic effects in the treatment of migraine headache by binding to 5-HT receptors located on intracranial blood vessels and sensory nerves of the trigeminal system.

Non-Clinical Toxicology

History of ischemic heart disease or coronary artery vasospasm ()

History of stroke or transient ischemic attack ()

Peripheral vascular disease ()

Ischemic bowel disease ()

Uncontrolled hypertension ()

Recent (within 24 hours) use of another 5-HTagonist (e.g., another triptan), or of an ergotamine-containing medication ()

Hemiplegic or basilar migraine ()

MAO-A inhibitor used in the past 2 weeks ()

Hypersensitivity to rizatriptan benzoate ()

Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, it should be used with caution in patients receiving such agents.

Antagonism has been demonstrated between clindamycin and erythromycin . Because of possible clinical significance, these two drugs should not be administered concurrently.

Rizatriptan benzoate should not be given to patients with ischemic or vasospastic coronary artery disease. There have been rare reports of serious cardiac adverse reactions, including acute myocardial infarction, occurring within a few hours following administration of rizatriptan benzoate. Some of these reactions occurred in patients without known coronary artery disease (CAD). 5-HT1 agonists including rizatriptan benzoate may cause coronary artery vasospasm (Prinzmetal's Angina), even in patients without a history of CAD. Triptan-naive patients who have multiple cardiovascular risk factors (e.g., increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD) should have a cardiovascular evaluation prior to receiving rizatriptan benzoate. If there is evidence of CAD or coronary artery vasospasm, rizatriptan benzoate should not be administered . For patients who have a negative cardiovascular evaluation, consideration should be given to administration of the first rizatriptan benzoate dose in a medically-supervised setting and performing an electrocardiogram (ECG) immediately following rizatriptan benzoate administration. Periodic cardiovascular evaluation should be considered in intermittent long-term users of rizatriptan benzoate who have cardiovascular risk factors.

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72

×

Tips

×

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).

Disclaimer: